FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3125655360> ?p ?o ?g. }

• W3125655360 endingPage "707" @default.
• W3125655360 startingPage "701" @default.
• W3125655360 abstract "<h3>Background</h3> “Head to head” studies comparing the efficacy and tolerability of different TNF inhibitors are scarce, in particular the comparison between certolizumab pegol and golimumab. <h3>Objectives</h3> To compare the efficaciousness, drug survival and tolerability of certolizumab-pegol and golimumab in adult patients with establish arthritis (RA, JIA, SpA or unspecified polyarthritis) starting these treatments between February 2010 and December 2013 at out-patient unit at the Skåne University Hospital, Department of Rheumatology Lund/Malmö and two associated private rheumatology units. <h3>Methods</h3> All patients starting treatment with biologics were consecutively included in the South Swedish Arthritis Treatment Group (SSATG) register and regularly followed up according the standard protocol including: SJC/TJC, CRP, ESR, physicians global assessment of disease activity, patients9 assessment of disease activity and pain (VAS global and VAS pain) and HAQ. Last follow up date was October 17th 2016. Kaplan-Meier survival analysis was used to estimate the drug survival. Possible predictors of drug survival were analysed using Cox regression model. <h3>Results</h3> In total, 352 patients (71% women, mean age 51 years, mean disease duration 12 years, started these treatments during study period. Of these, 168 received golimumab and 184 certulizumab-pegol. Mean treatment time was 31 months (range 0–77). Percentage of patients with RA, SpA, JIA and unspecified arthritis were 58,4%, 16,4%, 5,7%, and 19,5% respectively. Certolizumab-pegol was more used in RA (67% vs 49%) and JIA (8% vs 2%) while golimumab was more frequent among patients with SpA (21% and 12%) or PsA (23% and 10, respectively). Only 7% of golimumab and 10% of certulizumab-pegol patients received these drugs as first biologic treatment and approximately 50% of patients received these drugs as ≥3. biological treatment. In golimumab treated patients mean DAS28 decreased from 4,3 (baseline) to 3,3 (3 months); 2,8 (6 months) and 2,7 (12 months) but levelled off at 36 months follow up. Corresponding mean DAS28 levels in certulizumab-pegol treated patients were 4,6 (baseline); 3,2 (3 months); 2,8 (6 months) and 2,6 (12 months). The similar pattern was seen in changes in HAQ and CDAI over the study time. There were no statistically significant differences in DAS, HAQ or CDAI between treatments at any follow up visit. At the end of follow up 64 (38%) of golimumab and 60 (32%) of certulizumab-pegol patients remained on their treatment. No significant difference in drug survival was seen between the treatments (Figure). Patients with spondylartropathy had significantly better survival on golimumab compared to RA patients (p=0,005)whicih remained after adjustment for age, gender, CRP, number of previous biologics and concomitnt methotrexate at baseline. <h3>Conclusions</h3> Spondylarthropathy including psoriatic arthritis was associated with better drug survival on golimunab compared to certolizumab pegol. No other significant differences in efficacy, tolerability or drug survival were seen between golimumab and certolizumab pegol in patients with established arthritis in daily clinical practice. Approximately one third of patients starting these treatments remained on treatment after 3 years. <h3>Disclosure of Interest</h3> None declared" @default.
• W3125655360 created "2021-02-01" @default.
• W3125655360 creator A5024555645 @default.
• W3125655360 creator A5069475033 @default.
• W3125655360 date "2008-09-12" @default.
• W3125655360 modified "2023-10-18" @default.
• W3125655360 title "Optimal Public Goods Provision: Implications of Endogenizing the Labor/Leisure Choice" @default.
• W3125655360 cites W1532229780 @default.
• W3125655360 cites W1557575149 @default.
• W3125655360 cites W1984399289 @default.
• W3125655360 cites W1998819003 @default.
• W3125655360 cites W2084865421 @default.
• W3125655360 cites W2289004222 @default.
• W3125655360 cites W633381035 @default.
• W3125655360 doi "https://doi.org/10.3368/le.84.4.701" @default.
• W3125655360 hasPublicationYear "2008" @default.
• W3125655360 type Work @default.
• W3125655360 sameAs 3125655360 @default.
• W3125655360 citedByCount "15" @default.
• W3125655360 countsByYear W31256553602012 @default.
• W3125655360 countsByYear W31256553602015 @default.
• W3125655360 countsByYear W31256553602017 @default.
• W3125655360 countsByYear W31256553602019 @default.
• W3125655360 countsByYear W31256553602020 @default.
• W3125655360 crossrefType "journal-article" @default.
• W3125655360 hasAuthorship W3125655360A5024555645 @default.
• W3125655360 hasAuthorship W3125655360A5069475033 @default.
• W3125655360 hasBestOaLocation W31256553602 @default.
• W3125655360 hasConcept C126322002 @default.
• W3125655360 hasConcept C1862650 @default.
• W3125655360 hasConcept C197934379 @default.
• W3125655360 hasConcept C198451711 @default.
• W3125655360 hasConcept C2776215756 @default.
• W3125655360 hasConcept C2777077863 @default.
• W3125655360 hasConcept C2777575956 @default.
• W3125655360 hasConcept C2778375690 @default.
• W3125655360 hasConcept C2780132546 @default.
• W3125655360 hasConcept C2781290027 @default.
• W3125655360 hasConcept C71924100 @default.
• W3125655360 hasConceptScore W3125655360C126322002 @default.
• W3125655360 hasConceptScore W3125655360C1862650 @default.
• W3125655360 hasConceptScore W3125655360C197934379 @default.
• W3125655360 hasConceptScore W3125655360C198451711 @default.
• W3125655360 hasConceptScore W3125655360C2776215756 @default.
• W3125655360 hasConceptScore W3125655360C2777077863 @default.
• W3125655360 hasConceptScore W3125655360C2777575956 @default.
• W3125655360 hasConceptScore W3125655360C2778375690 @default.
• W3125655360 hasConceptScore W3125655360C2780132546 @default.
• W3125655360 hasConceptScore W3125655360C2781290027 @default.
• W3125655360 hasConceptScore W3125655360C71924100 @default.
• W3125655360 hasIssue "4" @default.
• W3125655360 hasLocation W31256553601 @default.
• W3125655360 hasLocation W31256553602 @default.
• W3125655360 hasLocation W31256553603 @default.
• W3125655360 hasOpenAccess W3125655360 @default.
• W3125655360 hasPrimaryLocation W31256553601 @default.
• W3125655360 hasRelatedWork W2011040773 @default.
• W3125655360 hasRelatedWork W2032482201 @default.
• W3125655360 hasRelatedWork W2033074403 @default.
• W3125655360 hasRelatedWork W2039099096 @default.
• W3125655360 hasRelatedWork W2065196715 @default.
• W3125655360 hasRelatedWork W2119512053 @default.
• W3125655360 hasRelatedWork W2741486190 @default.
• W3125655360 hasRelatedWork W2754098747 @default.
• W3125655360 hasRelatedWork W3125655360 @default.
• W3125655360 hasRelatedWork W2186374857 @default.
• W3125655360 hasVolume "84" @default.
• W3125655360 isParatext "false" @default.
• W3125655360 isRetracted "false" @default.
• W3125655360 magId "3125655360" @default.
• W3125655360 workType "article" @default.